Needham lowered the firm’s price target on Glaukos (GKOS) to $115 from $176 “due to lower peer multiples” but keeps a Buy rating on the shares. The company’s Q1 revenue beat consensus, and while management reiterated its 2025 revenue guidance, the implied iDose contribution increased by about $5M, the analyst tells investors in a research note. iDose reimbursement continues to expand, which should drive further adoption, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target lowered to $135 from $140 at Truist
- Wells downgrades Glaukos with iDose growth priced in
- Glaukos downgraded to Equal Weight from Overweight at Wells Fargo
- Positive Buy Rating for Glaukos Amid Strong iDose Performance and Awaited FDA Decision
- Glaukos’s Promising Outlook: Buy Rating Amid Strong Sales and Strategic Growth Opportunities